179 related articles for article (PubMed ID: 30279582)
1. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Freedland SJ; DeHoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Daskivich TJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):252-260. PubMed ID: 30279582
[TBL] [Abstract][Full Text] [Related]
2. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
3. Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer.
Freedland SJ; Pilon D; Bhak RH; Lefebvre P; Li S; Young-Xu Y
Urol Oncol; 2020 Dec; 38(12):930.e13-930.e21. PubMed ID: 32739230
[TBL] [Abstract][Full Text] [Related]
4. Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer.
Freedland SJ; Ramaswamy K; Huang A; Sandin R; Mardekian J; Schultz NM; Janjan N; George DJ
Clin Genitourin Cancer; 2023 Aug; 21(4):419-429. PubMed ID: 36842915
[TBL] [Abstract][Full Text] [Related]
5. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.
Patel SA; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):234-240. PubMed ID: 28117382
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
[TBL] [Abstract][Full Text] [Related]
7. Impact of Charlson comorbidity index varies by age in patients with prostate cancer treated by radical prostatectomy: a competing risk regression analysis.
Lee JY; Lee DH; Cho NH; Rha KH; Choi YD; Hong SJ; Yang SC; Cho KS
Ann Surg Oncol; 2014 Feb; 21(2):677-83. PubMed ID: 24145996
[TBL] [Abstract][Full Text] [Related]
8. Plain language summary: Does the amount of time it takes for prostate-specific antigen to double affect how long men with nonmetastatic castration-resistant prostate cancer live and their healthcare costs?
Freedland SJ; Ramaswamy K; Huang A; Sandin R; Schultz NM; Janjan N; George DJ
Future Oncol; 2023 Oct; 19(31):2075-2082. PubMed ID: 37646326
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial.
Bögemann M; Shore ND; Smith MR; Tammela TLJ; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Lebret T; Schostak M; Verholen F; Le Berre MA; Srinivasan S; Ortiz J; Mohamed AF; Sarapohja T; Fizazi K
Eur Urol; 2023 Mar; 83(3):212-221. PubMed ID: 36089529
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer.
Arnold P; Penaloza-Ramos MC; Adedokun L; Rees S; Lockhat M; Spary L; Watkins A; Gnanapragasam V; Crabb SJ
Sci Rep; 2021 Nov; 11(1):22151. PubMed ID: 34772971
[TBL] [Abstract][Full Text] [Related]
11. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
12. How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
He H; Han D; Xu F; Lyu J
Prostate; 2022 Mar; 82(4):415-424. PubMed ID: 34927741
[TBL] [Abstract][Full Text] [Related]
13. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Vidal AC; Howard LE; de Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Freedland SJ
BJU Int; 2018 Jul; 122(1):76-82. PubMed ID: 29521009
[TBL] [Abstract][Full Text] [Related]
14. Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer.
Boehm K; Dell'Oglio P; Tian Z; Capitanio U; Chun FKH; Tilki D; Haferkamp A; Saad F; Montorsi F; Graefen M; Karakiewicz PI
World J Urol; 2017 Jul; 35(7):1031-1036. PubMed ID: 27796538
[TBL] [Abstract][Full Text] [Related]
15. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach.
Lee JY; Kang HW; Rha KH; Cho NH; Choi YD; Hong SJ; Cho KS
J Cancer Res Clin Oncol; 2016 Apr; 142(4):849-58. PubMed ID: 26660495
[TBL] [Abstract][Full Text] [Related]
16. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
[TBL] [Abstract][Full Text] [Related]
17. Impact of comorbidities at diagnosis on prostate cancer treatment and survival.
Matthes KL; Limam M; Pestoni G; Held L; Korol D; Rohrmann S
J Cancer Res Clin Oncol; 2018 Apr; 144(4):707-715. PubMed ID: 29417258
[TBL] [Abstract][Full Text] [Related]
18. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
Goyal J; Pond GR; Galsky MD; Hendricks R; Small A; Tsao CK; Sonpavde G
Urol Oncol; 2014 Jan; 32(1):36.e27-34. PubMed ID: 23685020
[TBL] [Abstract][Full Text] [Related]
19. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Pratson CL; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):333-7. PubMed ID: 26171882
[TBL] [Abstract][Full Text] [Related]
20. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
